Riken Vitamin Co., Ltd. (JP:4526)
:4526
Want to see JP:4526 full AI Analyst Report?
Top Page
Riken Vitamin Co., Ltd.
(4526)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥3,018.00
▲(1.72% Upside)
Action:Downgraded
Date:05/15/26
The score is driven mainly by solid financial strength (low leverage and acceptable profitability) and supportive valuation (low P/E and ~4% yield). These positives are tempered by notably weak technicals (downtrend with oversold momentum) and a key fundamental risk: the sharp 2026 drop in free cash flow and softer margins.
Positive Factors
Conservative balance sheet
Very low leverage and a large equity base give the company durable financial flexibility. With debt-to-equity near 0.09, Riken Vitamin can fund R&D, absorb demand shocks, maintain dividends or invest in strategic acquisitions without pressuring liquidity over the next several quarters.
Negative Factors
Sharp FCF decline
A large fall in free cash flow reduces the firm's ability to self-fund capex, pay dividends, or pursue bolt-on M&A without altering financing. If persistent, this weaker cash generation erodes financial resilience and increases reliance on internal working-capital management or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a large equity base give the company durable financial flexibility. With debt-to-equity near 0.09, Riken Vitamin can fund R&D, absorb demand shocks, maintain dividends or invest in strategic acquisitions without pressuring liquidity over the next several quarters.
Read all positive factors
Riken Vitamin Co., Ltd. (4526) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥63.51B
Dividend Yield3.63%
Average Volume (3M)91.61K
Price to Earnings (P/E)12.1
Beta (1Y)0.53
Revenue Growth0.75%
EPS Growth-23.19%
CountryJP
Employees1,857
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)293.59
Shares Outstanding30,705,100
10 Day Avg. Volume57,120
30 Day Avg. Volume91,606
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.02
Price to Sales (P/S)0.88
P/FCF Ratio91.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)213.9
Revenue Forecast (FY)¥96.20B
Riken Vitamin Co., Ltd. Business Overview & Revenue Model
Company Description
Riken Vitamin Co., Ltd. engages in the food ingredient, food application, health care, and chemical businesses in Japan. It offers food emulsifies for use in bread, cake, whipped topping, coffee cream, margarine, tofu, jam, marmalade, ice cream, c...
How the Company Makes Money
Riken Vitamin makes money primarily by selling (1) food ingredients and food-processing materials to business customers and (2) finished/consumer food products through retail and other distribution channels. In its ingredients-oriented activities,...
Riken Vitamin Co., Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 95.21B | 96.30B | 95.58B | 91.48B | 88.75B | 79.23B |
| Gross Profit | 30.97B | 29.77B | 31.27B | 29.89B | 27.24B | 25.57B |
| EBITDA | 15.63B | 11.58B | 16.04B | 15.35B | 11.71B | 24.23B |
| Net Income | 8.84B | 7.04B | 9.39B | 8.76B | 6.41B | 21.58B |
Balance Sheet | ||||||
| Total Assets | 112.78B | 116.39B | 113.00B | 118.78B | 105.22B | 102.66B |
| Cash, Cash Equivalents and Short-Term Investments | 20.05B | 20.07B | 22.30B | 23.38B | 19.16B | 17.30B |
| Total Debt | 10.13B | 7.14B | 9.98B | 16.09B | 14.60B | 17.57B |
| Total Liabilities | 33.72B | 33.01B | 33.80B | 42.13B | 33.85B | 36.12B |
| Stockholders Equity | 79.02B | 83.34B | 79.16B | 76.61B | 71.34B | 66.52B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 925.00M | 3.12B | 7.42B | 5.67B | 3.44B |
| Operating Cash Flow | 0.00 | 5.96B | 7.89B | 10.45B | 7.83B | 6.82B |
| Investing Cash Flow | 0.00 | 1.75B | 353.00M | -554.00M | -2.03B | -3.66B |
| Financing Cash Flow | 0.00 | -8.04B | -9.96B | -7.08B | -4.58B | -7.57B |
Riken Vitamin Co., Ltd. Technical Analysis
Neutral
2967.00
Price Trends
2839.39
Negative
2922.96
Negative
2864.29
Negative
Market Momentum
-24.71
Negative
48.30
Neutral
64.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4526, the sentiment is Neutral. The current price of 2967 is above the 20-day moving average (MA) of 2767.35, above the 50-day MA of 2839.39, and above the 200-day MA of 2864.29, indicating a neutral trend. The MACD of -24.71 indicates Negative momentum. The RSI at 48.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4526.
Riken Vitamin Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥4.74T | 23.62 | 9.46% | 1.32% | 3.47% | 99.65% | |
67 Neutral | ¥63.51B | 12.06 | ― | 3.63% | 0.75% | -23.19% | |
64 Neutral | ¥11.86B | 11.86 | ― | 3.94% | 1.95% | -9.34% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥403.62B | 17.26 | ― | 2.42% | 1.83% | 340.84% | |
59 Neutral | ¥31.84B | 12.38 | ― | 3.84% | 4.65% | 10.02% | |
51 Neutral | ¥305.85B | 27.71 | ― | 1.45% | 15.06% | 399.49% |
* Consumer Defensive Sector Average
JP:4526
Riken Vitamin Co., Ltd.
2,783.00
377.74
15.70%
JP:2802
Ajinomoto Co
5,176.00
1,864.39
56.30%
JP:2264
Morinaga Milk Industry Co., Ltd.
4,684.00
1,533.79
48.69%
JP:2607
Fuji Oil Holdings, Inc.
3,591.00
707.56
24.54%
JP:2927
AFC-HD AMS Life Science Co., Ltd.
836.00
15.86
1.93%
JP:3139
Lacto Japan Co., Ltd.
3,175.00
-61.50
-1.90%
Riken Vitamin Co., Ltd. Corporate Events
Riken Vitamin Hits Record Sales but Profit Falls as Overseas Slump and Asbestos Charge Bite
May 13, 2026
Riken Vitamin reported record net sales of ¥96.3 billion for the year ended March 31, 2026, its fifth consecutive annual increase, but saw operating profit fall 20.9% to ¥6.9 billion and ROE drop to 8.7%. Domestic Food and Chemical opera...
Riken Vitamin Posts Profit Decline but Lifts Dividend and Expands in Southeast Asia
May 13, 2026
Riken Vitamin reported marginally higher consolidated net sales of ¥96.3 billion for the fiscal year ended March 31, 2026, but saw operating profit drop 20.9% to ¥6.9 billion and profit attributable to owners fall 25.1% to ¥7.0 bill...
Riken Vitamin Announces ¥2 Billion Share Buyback to Boost Shareholder Returns
May 13, 2026
Riken Vitamin’s board has approved a share buyback of up to 900,000 common shares, equivalent to 3.08% of its outstanding stock, with a maximum outlay of ¥2 billion. The repurchase, to be executed via market purchases on the Tokyo Stock...
Riken Vitamin Reshapes Top Management Ahead of June 2026 Shareholders Meeting
Apr 27, 2026
Riken Vitamin has announced changes to its top management, with the Board of Directors resolving to alter its representative director and director lineup following the upcoming 90th Annual General Meeting of Shareholders on June 23, 2026. Senior M...
Riken Vitamin Nears Full Use of ¥2 Billion Share Buyback Authorization
Mar 24, 2026
Riken Vitamin Co., Ltd. has completed an additional repurchase of 53,300 shares of its common stock on the Tokyo Stock Exchange between March 1 and March 23, 2026, at a total cost of ¥156,067,693. This latest transaction forms part of a broad...
Riken Vitamin Advances Toward Completion of ¥2 Billion Share Buyback Program
Mar 2, 2026
Riken Vitamin Co., Ltd. has reported progress on its ongoing share repurchase program, acquiring 57,300 shares of its common stock on the Tokyo Stock Exchange between February 1 and February 28, 2026, at a total cost of 179,067,993 yen. This buyba...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.